A recent study, utilizing both in vitro human endothelial cells and an in vivo mouse model, provided strong evidence that ruscogenin exhibits considerable efficacy in sepsis treatment and blocks specifically MIR-146a-5p and, in parallel, activates NPR2 and SSH1 [65]. This evidence concerns the gene NPR2 and Sepsis.